Cargando…
Checkpoint-Inhibitoren – Indikation und Verwendung bei Melanompatienten
Since its introduction in 2011 the checkpoint inhibitor ipilimumab, has revolutionized the whole of oncology. After this first major step more checkpoint inhibitors, such as the PD‑1 antibodies nivolumab and pembrolizumab have been developed. The results are groundbreaking, especially in advanced ma...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550369/ https://www.ncbi.nlm.nih.gov/pubmed/32926216 http://dx.doi.org/10.1007/s00393-020-00870-8 |